New combo attack on rare blood cancer shows promise in early trial
NCT ID NCT07502768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, not cure it, and participants will need ongoing monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200043, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Immunotherapy combo may outperform chemo in rare lymphoma
- New hope for tough lymphoma: TR115 faces off against standard care
- New drug duo targets hard-to-treat blood cancers
- Engineered donor cells take aim at tough blood cancers in early trial
- New blood test could help monitor T-Cell lymphoma